- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01723319
A Double Blind Randomized Controlled Evaluation of the HBLPADD-coil Transcranial Magnetic Stimulation (TMS) Device - Efficacy and Safety In Subjects With ADHD.
Objectives:The purpose of the study is to explore the efficacy and safety of HBLPADD Coil deep brain TMS in subjects with ADHD.
Patient Population: The intention is to treat 40 patients diagnosed with ADHD. The patients will be of all racial, ethnic and gender categories, ranging from 18 to 65 years of age.
Structure: The study is a randomized, prospective, 5 weeks, double blind study. Blinding: The treatment administrator and the study personnel and patients will be masked to the treatment being administrated.
The study group will receive active dTMS treatment and the control group will receive an inactive, sham treatment
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Yechiel levkovitz, MD
- Phone Number: 972-9-7478644
- Email: ylevk@clalit.org.il
Study Locations
-
-
-
Hod hasharon, Israel
- Shalvata
-
Contact:
- Yechiel levkovitz, MD
- Phone Number: 972-9-7478644
- Email: ylevk@clalit.org.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients between the ages of 18-65(male and female).
- Diagnosed as suffering from Attention-Deficit Hyperactivity Disorder according to the DSM IV.
- Patients taking medication for ADHD will give their consent to stop those medication 48 before entering the study and throughout the daily treatments.
- Gave informed consent for participation in the study.
- If referred by the treating psychiatrist, he or she approves of the subjects participation in the study.
Exclusion Criteria:
- Suffering from other diagnosis on axis 1.
- antipsychotic treatment with stabilizers; medications from the Benzodiazepines group are allowed, if need be,to a maximum dosage of 2 mg lorazepam.
- History of lack of tolerance to TMS.
- Axis 2 diagnosis according to the DSM IV.
- Substantial suicidal risk as judged by the treating psychiatrist or by an independent psychiatrist.
- Attempted suicide in the past year.
- High and not controlled blood pressure.
- History of epilepsy, seizure, or hot spasm.
- History of epilepsy or seizure in first degree relatives.
- History of a significant head injury
- History of metal in the head (outside the mouth space).
- Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps.
- Use of hearing aids for hearing loss.
- History of frequent or severe headaches.
- History of drug or alcohol abuse during the last year.
- Inability to achieve satisfying level of communication with the subject.
- Participation in current clinical study or clinical study within 30 days prior to this study
- Patients declared as legally incompetent, with an appointed physical guardian and/or cannot sign informed consent due to cognitive incompetence.
- Women - Pregnancy or not using a reliable method of birth control.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 1
deep TMS treatment
|
20 daily deep TMS treatment
|
SHAM_COMPARATOR: 2
inactive treatment
|
inactive treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy will be examined by the change in the CAARS questionnaire from the baseline visit to the determination visit in the treatment group compared to the control group.
Time Frame: 5 weeks
|
5 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
clinical improvement as measured using Clinical global Impression (CGI).
Time Frame: 5 weeks
|
5 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SH-0025-12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on ADHD
-
Okinawa Institute of Science and Technology Graduate...Japan society for the promotion of science; Miyazaki International CollegeRecruiting
-
King's College LondonSouth London and Maudsley NHS Foundation TrustNot yet recruiting
-
Universidad de GranadaNot yet recruiting
-
Izmir Katip Celebi UniversityDokuz Eylul UniversityNot yet recruiting
-
Seattle Children's HospitalNational Institute of Mental Health (NIMH); University of WashingtonRecruiting
-
University of California, DavisRecruiting
-
Chen LiRecruiting
-
Region SyddanmarkRecruiting
-
Hugo W. Moser Research Institute at Kennedy Krieger...Active, not recruiting
Clinical Trials on HBLPADD coil deep TMS
-
BeerYaakov Mental Health CenterWeizmann Institute of ScienceUnknown
-
BrainswayUnknownMild Cognitive ImpairmentIsrael
-
St. Joseph's Healthcare HamiltonPeter Boris Centre for Addictions Research (PBCAR)Recruiting
-
Centre for Addiction and Mental HealthCanadian Institutes of Health Research (CIHR); BrainswayCompleted
-
BrainswayCompletedMajor Depressive DisorderUnited States, Canada, Germany, Israel, France
-
Shalvata Mental Health CenterCompleted
-
Shalvata Mental Health CenterUnknownMarijuana AbuseIsrael
-
BrainswayCompletedMajor Depressive Disorder, Recurrent, Unspecified | Major Depressive Disorder, Single Episode, UnspecifiedUnited States, Canada, Germany, Israel
-
Rotman Research Institute at BaycrestCentre for Addiction and Mental Health; BrainswayRecruiting
-
Shalvata Mental Health CenterUnknown